Valeo Pharma Inc (TSX:VPH)

C$ 0.045 0 (0%) Market Cap: 4.44 Mil Enterprise Value: 67.40 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 0/100

Q3 2024 Valeo Pharma Inc Earnings Call Transcript
Sep 13, 2024

C$0.065 (-13.33%)

Earnings
Q2 2024 Valeo Pharma Inc Earnings Call Transcript
Jun 14, 2024

C$0.11 (-29.03%)

Earnings
Q1 2024 Valeo Pharma Inc Earnings Call Transcript
Mar 15, 2024

C$0.18 (-7.69%)

Earnings
Q4 2023 Valeo Pharma Inc Earnings Call Transcript
Jan 30, 2024

C$0.285 (-13.64%)

Earnings
Q2 2023 Valeo Pharma Inc Earnings Call Transcript
Jun 14, 2023

C$0.38 (+7.04%)

Earnings
Valeo Pharma Inc at Bloom Burton & Co Healthcare Investor Conference Transcript
Apr 25, 2023
Q1 2023 Valeo Pharma Inc Earnings Call Transcript
Mar 16, 2023

C$0.53 (-1.85%)

Earnings
Valeo Pharma Inc at OTC Markets Life Science Investor Forum (Virtual) Transcript
Mar 09, 2023
Q2 2022 Valeo Pharma Inc Earnings Call Transcript
Jun 15, 2022

C$0.54 (+3.85%)

Earnings
Valeo Pharma Inc at Bloom Burton & Co. Healthcare Investor Conference Transcript
May 03, 2022
Q1 2022 Valeo Pharma Inc Earnings Call Transcript
Mar 25, 2022

C$0.66 (-1.49%)

Earnings
Q3 2021 Valeo Pharma Inc Earnings Call Transcript
Sep 23, 2021

C$0.71 (-1.39%)

Earnings
Q2 2021 Valeo Pharma Inc Earnings Call Transcript
Jun 30, 2021

C$0.82 (-1.20%)

Earnings
Q1 2021 Valeo Pharma Inc Earnings Call Transcript
Apr 01, 2021

C$1.09 (-9.92%)

Earnings
Q4 2020 Valeo Pharma Inc Earnings Call Transcript
Feb 25, 2021

C$0.99 (-8.33%)

Earnings

Valeo Pharma Inc at Bloom Burton & Co Healthcare Investor Conference Transcript

Apr 25, 2023 / 03:00PM GMT

Release Date Price: C$0.49 (-1.01%)

Transcript

Unidentified Analyst

(Conference Instructions)

Our next presentation is Valeo Pharma. Joining us today is Steve Saviuk, the CEO. At the end of his presentation, we'll have five minutes for questions-and-answers. Steve, take it away. Thank you.

Steve Saviuk

Valeo Pharma Inc. - CEO

Thank you very much. Thanks, everyone, for coming and listening to Valeo presentation. I'd like to thank Bloom Burton, Jolyon, and Brian, and all the team for putting on a wonderful event that supports Canadian health care companies. And maybe a little special shout out [bolivin] family, whose deal announced last week sheds a little light on what has been a dismal capital markets for some time for the healthcare business. Hopefully that deal will be the turning point, and we'll start seeing some valuations reflect more appropriately the value in the future of Canadian companies.

Next slide, please. Forward-looking statements. You've been in this room, you've heard quite a few of them. I encourage you to read it quickly, and we'll move on to the presentation. Next slide.

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.